Hospital plays key role in pre-eclampsia study
29 October 2017
Southend Hospital has played a leading role in a new study into the effectiveness of aspirin in reducing the chances of pregnant women developing pre-eclampsia.
Results, published in the New England Journal of Medicine,
revealed a daily 150mg aspirin dose reduces the pre-eclampsia risk
by 82% in babies born before 34 weeks.
Pre-eclampsia occurs in nearly one in 10 pregnancies in the UK
and it can lead to
significant harm to mothers and babies. There is no treatment so
the main aim is to manage blood pressure and deliver babies at the
right time. Aspirin lowers the risk by 62% in babies born
before 37 weeks.
Mr Mandeep Singh, Consultant Fetal Maternal Medicine, said:
"Southend Hospital was one of the few centres in UK that
participated in the study. We screened almost 91% of the pregnancy
population in Southend, which was the highest in any centre taking
part in the study across the world."
The success of this study and the hospital's leading role in it
boosts the Trust's credentials as a research centre.
The hospital is rated fourth best in the north Thames region for
reproductive health research, well above some of the larger London